viewFutura Medical PLC

Futura completes landmark ED phase III dosing, expects data by year end

In the same announcement, it said recruitment for a one-year, open-label extension study involving 1,000 men had been successfully concluded

Futura Medical PLC -

Futura Medical PLC (LON:FUM) said it expects to have the headline data from its erectile dysfunction drug (ED) by the end of the year after completing dosing for the European phase III clinical trial.

Chief executive James Barder said the release of healding findings from the FM57 study would be a “key value inflection point” for the company.

In the same announcement, the company said recruitment for a one-year, open-label extension study involving 1,000 men had been successfully concluded.

This will assess the long-term safety and tolerability of the gel product and is a standard regulatory requirement for drugs intended for extended treatment of non-life-threatening conditions.

"It is estimated that one in six men will experience some form of ED in their lives,” CEO Barder said.

“We believe MED2005 will offer new hope to ED suffers, in an area that has seen little innovation for nearly two decades and has the potential to be a first line treatment option for ED."

The Futura gel uses the company’s DermaSys technology to direct the active ingredient through the skin.

This means it has a faster onset than the blue pills used for erectile dysfunction, which tend to take up to 20 minutes. And MED2005 is known to avoid some of the side-effects of traditional medication.

Quick facts: Futura Medical PLC

Price: 18.344 GBX

Market: AIM
Market Cap: £44.35 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...



Futura Medical CEO talks regulatory timeline and commercial potential for...

Futura Medical PLC's (LON:FUM)  James Barder caught up with Proactive London's Andrew Scott on the back of their 2019 results. He says the EU filing for MED3000 is likely by the end of July, with the US Food & Drug Administration submission expected by the end of the third...

on 1/4/20

2 min read